SM
APVO icon

Sabby Management’s Aptevo Therapeutics APVO Stock Holding History

Sabby Management’s Portfolio APVO Stock Details APVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-38
Closed -$153K – 44
2024
Q2 		$153K Buy
+38
New +$567K 0.1% 21
2024
Q1 		– Sell
-1
Closed -$63.3K – 58
2023
Q4 		$63.3K Sell
1
-1
-50% -$142K 0.06% 38
2023
Q3 		$440K Buy
+2
New +$822K 0.32% 19

Other funds holding APVO

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sabby Management's APVO Position: Q3 2024 in Review

Sabby Management sold out of Aptevo Therapeutics (APVO) in Q3 2024, closing a stake of 38 shares — an estimated $153K sold.

Sabby Management first reported a position in APVO in Q3 2023 and held it in 3 quarters. The position peaked at $440K in Q3 2023. 10 funds tracked by Wall St. Rank hold APVO as of Q3 2024.

  • Sabby Management reported no remaining Aptevo Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Sabby Management sold 38 Aptevo Therapeutics shares in Q3 2024, an estimated $153K.
  • Sabby Management first reported a position in Aptevo Therapeutics in Q3 2023 and held it in 3 quarters.
  • Sabby Management's Aptevo Therapeutics position peaked at $440K in Q3 2023.
  • 10 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q3 2024.

Based on Sabby Management's 13F filing for Q3 2024, filed 14 Nov 2024.